News | July 21, 2025
Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders
Subscribe To Our Newsletter & Stay Updated
